Previous 10 | Next 10 |
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage...
2023-06-29 09:11:33 ET Eiger BioPharmaceuticals ( NASDAQ: EIGR ) announced Thursday its intention to reduce 25% of its workforce amid plans to reorganize its portfolio following a strategic review. The Palo Alto, California-based biotech focused on rare diseases also announced t...
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO PR Newswire Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-...
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow PR Newswire Company to host conference call and live webcast on Thursday, June 29 , at 8:30 am ET PALO ALTO, Calif. , June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasd...
2023-06-16 20:24:53 ET Summary Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way. This is my second Eiger BioPharmaceuticals (EIGR) article following 02/2023's "Eiger BioPharma...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
2023-05-11 17:02:59 ET Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q1 GAAP EPS of -$0.52 misses by $0.12 . Revenue of $4.1M (+53.6% Y/Y) beats by $0.28M . Cost of sales was flat for the three months ended March 31, 2023 compared to the same perio...
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in...
2023-04-13 08:38:21 ET Eiger BioPharmaceuticals ( NASDAQ: EIGR ) has announced the appointments of William G. Kachioff as CFO, and James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary. "We are excited to welcome two seasoned biotech executi...
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments PR Newswire William G. Kachioff appointed as Chief Financial Officer James A. Vollins appointed as General Counsel, Chief Compliance Officer and Corporate Secretary PALO ALTO, Calif. ...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...